What is claimed is:

1. A pharmaceutical formulation comprising an enteric protectant and a compound of the formula:



wherein:

E_1 is $-CO_2H$, $-CO_2R_5$, $-CO_2R_{5a}W_5$ or $-CO_2W_5$;

G_1 is $-N_3$, $-N(R_{11})_2$, $-N(R_{11})C(N(R_{11}))(N(R_{11})_2)$, or $-C(R_{11})_2-N(R_{11})_2$;

T_1 is $-NH(C(O)CH_3)$, $-NH(C(O)CH_2F)$, $-NH(C(O)CHF_2)$, or $-NH(C(O)CF_3)$;

U_1 is $-OR_4$, $-SR_4$, NHR_4 or $N(R_4)_2$;

R_1 is independently H or alkyl of 1 to 12 carbon atoms;

R_2 is independently R_3 or R_4 wherein each R_4 is independently substituted with 0 to 3 R_3 groups;

R_3 is independently F, Cl, Br, I, -CN, N_3, $-NO_2$, $-OR_{6a}$, $-OR_1$, $-N(R_1)_2$, $-N(R_1)(R_{6b})$, $-N(R_{6b})_2$, $-SR_1$, $-SR_{6a}$, $-S(O)R_1$, $-S(O)_2R_1$, $-S(O)OR_1$, $-S(O)OR_{6a}$, $-S(O)_2OR_1$, $-S(O)_2OR_{6a}$, $-C(O)OR_1$, $-C(O)R_{6c}$, $-C(O)OR_{6a}$, $-OC(O)R_1$, $-N(R_1)(C(O)R_1)$, $-N(R_{6b})(C(O)R_1)$, $-N(R_1)(C(O)OR_1)$, $-N(R_{6b})(C(O)OR_1)$, $-C(O)N(R_1)_2$, $-C(O)N(R_{6b})(R_1)$, $-C(O)N(R_{6b})_2$, $-C(NR_1)(N(R_1)_2)$, $-C(N(R_{6b}))(N(R_1)_2)$, $-C(N(R_1))(N(R_1)(R_{6b}))$, $-C(N(R_{6b}))(N(R_1)(R_{6b}))$, $-C(N(R_1))(N(R_{6b})_2)$, $-C(N(R_{6b}))(N(R_{6b})_2)$, $-N(R_1)C(N(R_1))(N(R_1)_2)$, $-N(R_1)C(N(R_1))(N(R_1)(R_{6b}))$, $-N(R_1)C(N(R_{6b}))(N(R_1)_2)$, $-N(R_{6b})C(N(R_1))(N(R_1)_2)$, $-N(R_{6b})C(N(R_{6b}))(N(R_1)_2)$, $-N(R_{6b})C(N(R_1))(N(R_1)(R_{6b}))$, $-N(R_1)C(N(R_{6b}))(N(R_1)(R_{6b}))$, $-N(R_1)C(N(R_1))(N(R_{6b})_2)$, $-N(R_{6b})C(N(R_{6b}))(N(R_1)(R_{6b}))$, $-N(R_{6b})C(N(R_1))(N(R_{6b})_2)$, $-N(R_1)C(N(R_{6b}))(N(R_{6b})_2)$, $-N(R_{6b})C(N(R_{6b}))(N(R_{6b})_2)$, =O, =S, $=N(R_1)$, or $=N(R_{6b})$;

R_4 is independently alkyl of 1 to 12 carbon atoms, alkenyl of 2 to 12

carbon atoms, or alkynyl of 2 to 12 carbon atoms; and

R_5 is independently R_4 wherein each R_4 is substituted with 0 to 3 R_3 groups;

R_{5a} is independently alkylene of 1 to 12 carbon atoms, alkenylene of 2 to 12 carbon atoms, or alkynylene of 2-12 carbon atoms any one of which alkylene, alkenylene or alkynylene is substituted with 0-3 R_3 groups

R_{6a} is independently H or an ether- or ester-forming group;

R_{6b} is independently H, a protecting group for amino or the residue of a carboxyl-containing compound;

R_{6c} is independently H or the residue of an amino-containing compound;

W_5 is carbocycle or heterocycle wherein W_5 is independently substituted with 0 to 3 R_2 groups; and

R_{11} is independently H or R_5.

2. The pharmaceutical formulation of claim 1 wherein E_1 is $-CO_2R_5$; G_1 is NH_2 or N_3; T_1 is $NHC(O)CH_3$; and U_1 is $-OR_4$.

3. The pharmaceutical formulation of claim 2 wherein E_1 is $C(O)OCH_2CH_3$; G_1 is NH_2; T_1 is $NHC(O)CH_3$; and U_1 is $OCH(CH_2CH_3)_2$.

4. The pharmaceutical formulation of claim 1 comprising a compound of the formula:



5. The pharmaceutical formulation of claim 4 wherein the

compound further comprises a phosphate salt.

6. The pharmaceutical formulation of claim 1 comprising a compound of the formula:



7. The pharmaceutical formulation of claim 1 wherein the enteric protectant is selected from cellulose acetate phthalate polymer, methyl acrylate-methacrylic acid copolymer, cellulose acetate succinate polymer, hydroxypropylmethylcellulose phthalate polymer, polyvinyl acetate phthalate polymer, cellulose acetate trimellitate polymer, hydroxypropyl methylcellulose phthalate succinate polymer, methacrylic acid polymer, and methacrylic acid ester polymer.

8. The pharmaceutical formulation of claim 1wherein the formulation is a tablet.

9. The pharmaceutical formulation of claim 1 wherein the formulation is a capsule.

10. A pharmaceutical formulation comprising a liquid suspension of enteric coated particles of a compound of claim 1.

11. A method of inhibiting the activity of neuraminidase comprising the step of contacting a sample suspected of containing neuraminidase with a pharmaceutical formulation of claim 1.

12. The method of claim 11 wherein the neuraminidase is influenza neuraminidase *in vivo*.

13. A method for the treatment or prophylaxis of influenza infection in a host comprising administering to the host a therapeutically effective amount of a pharmaceutical formulation of claim 1.